A randomized phase III double-blind placebo-controlled trial of first-line chemotherapy and trastuzumab with or without bevacizumab for patients with HER2/neu-positive metastatic breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1105)
Titel:
A randomized phase III double-blind placebo-controlled trial of first-line chemotherapy and trastuzumab with or without bevacizumab for patients with HER2/neu-positive metastatic breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1105)
Auteur:
Mezzanotte-Sharpe, Jessica ONeill, Anne Mayer, Ingrid A. Arteaga, Carlos L. Yang, Ximing J. Wagner, Lynne I. Cella, David Meropol, Neal J. Alpaugh, R. Katherine Saphner, Thomas J. Swaney, Robert E. Hoelzer, Karen L. Gradishar, William J. Abramson, Vandana G. Sundaram, P. Kothai Jilani, Shamim Z. Perez, Edith A. Lin, Nancy U. Jahanzeb, Mohammad Wolff, Antonio C. Sledge, George W. Reid, Sonya A.